Expanding HBV Treatment Candidacy

In this downloadable slideset, review criteria for initiating HBV therapy, opportunities to broaden candidacy for treatment, and the potential biologic consequences of untreated infection.
Ira M. Jacobson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.11 MB
Released: June 21, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences

Related Content

Download free expert-authored slides on the clinical interplay of HCV and COVID-19 coinfection and the impact of the COVID-19 pandemic on access to HCV care and treatment

Ricardo Franco, MD Stacey Trooskin, MD, PhD Released: October 7, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

CCO commentary from Anna Christina L. dela Cruz, MD, on the use of quantitative HBsAg and elastography in the management of hepatitis B

Anna Christina L. dela Cruz, MD Released: August 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue